Boston Scientific has priced $3 billion of U.S. dollar bonds and €4.25 billion of euro bonds to help fund its planned acquisition of Penumbra. The debt is expected to close on December 1, 2026; the euro bonds will be issued by an indirect wholly owned financing subsidiary and guaranteed by Boston Scientific.
The financing is not dependent on the Penumbra deal closing. But if the acquisition is abandoned or misses its deadline, most of the new bonds must be redeemed at a premium.
Key details
- U.S. dollar bonds: Boston Scientific will issue:
- $1 billion of 5.375% notes due 2029
- $750 million of 5.500% notes due 2031
- $750 million of 5.750% notes due 2033
-
$500 million of 5.875% notes due 2036
-
Euro bonds: Its financing subsidiary, American Medical Systems Europe, will issue €4.25 billion of notes, guaranteed by Boston Scientific:
- €500 million of floating-rate notes due 2028
- €500 million of 3.875% notes due 2028
- €750 million of 4.125% notes due 2030
- €750 million of 4.500% notes due 2034
- €1 billion of 4.750% notes due 2038
-
€750 million of 5.125% notes due 2046
-
Use of proceeds: Boston Scientific expects to use the net proceeds, along with short-term borrowing, credit-facility borrowing and cash on hand, to fund the cash portion of its previously announced Penumbra acquisition and pay related costs. Any proceeds left over may go toward general corporate purposes, including reducing short-term debt, working capital or potential acquisitions.
-
Redemption if the acquisition does not proceed: If the Penumbra transaction is not completed by the applicable deadline—or Boston Scientific and its subsidiary notify the bond trustee that they will not pursue it—the company must redeem each series of the U.S. dollar and euro notes at 101% of principal, plus accrued unpaid interest. The floating-rate euro notes are excluded from this special redemption requirement. The deadline starts with January 14, 2027, but may be extended under the acquisition agreement, potentially as late as January 14, 2028.
Plain-English implications
The offering adds substantial debt to finance the acquisition, with maturities stretching from 2028 to 2046. Boston Scientific remains responsible for the euro notes through its guarantee. The special redemption provision links most of the new debt to the Penumbra deal, even though the bond sales can close before the acquisition.
